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Certain mutant strains of herpes simplex virus type 1 (HSV-1) are unable to infect cells in which entry is dependent on
HVEM, the previously described herpesvirus entry mediator designated here as herpesvirus entry protein A (HveA). These
mutant viruses can infect other cells where entry is apparently dependent on other co-receptors. The mutant virus
HSV-1(KOS)Rid1 was used to screen a human cDNA expression library for ability of transfected plasmids to convert resistant
Chinese hamster ovary cells to susceptibility to virus entry. A plasmid expressing the previously described poliovirus
receptor-related protein 2 (Prr2) was isolated on the basis of this activity. This protein, designated here as HveB, was shown
to mediate the entry of three mutant HSV-1 strains that cannot use HVEM as co-receptor, but not wild-type HSV-1 strains.
HveB also mediated the entry of HSV-2 and pseudorabies virus but not bovine herpesvirus type 1. HveB was expressed in
some human neuronal cell lines, fibroblastic cells, keratinocytes, and primary activated T lymphocytes. Antibodies specific
for HveB blocked infection of HveB-expressing CHO cells and a human fibroblastic cell strain HEL299. Differences in ability
of HSV-1 and HSV-2 strains to use HveB for entry should influence the types of cells that can be infected and thereby account
in part for serotype and strain differences in tissue tropism and pathogenicity. © 1998 Academic Press
INTRODUCTION
Members of the alphaherpesvirus subfamily of the
herpesviruses typically have a broad host range and a
short replicative cycle, are highly cytotoxic to cultured
cells, and can establish latent infections in cells of the
nervous system of the natural host (Roizman, 1993). Hu-
man and animal representatives of the alphaherpesvirus
subfamily exhibit common requirements for entry into
cells (Mettenleiter, 1995; Spear, 1993). In most cases, five
viral envelope glycoproteins (gB, gC, gD, gH, and gL)
mediate virus binding to cells and entry. The initial inter-
action of virus with cells is the binding of gC, and in
some cases also gB, to cell surface glycosaminoglycans
(GAGs), preferentially heparan sulfate. Although gC is
dispensible for the infection of many cultured cells, gB,
gD, gH, and gL are required for mediating the fusion
between virion envelope and cell membrane that allows
viral penetration. Various lines of evidence point to inter-
action of some of these envelope glycoproteins, partic-
ularly gD, with cell surface receptors other than heparan
sulfate and to competition among alphaherpesviruses for
binding to gD receptors (Campadelli-Fiume et al., 1988;
Chase et al., 1993; Johnson et al., 1990; Johnson and
Ligas, 1988; Karger and Mettenleiter, 1993; Lee and
Fuller, 1993; Liang et al., 1991; Petrovskis et al., 1988).
Recently, an expression cloning assay was devised for
isolating plasmids encoding cell surface proteins that
can mediate herpes simplex virus type 1 (HSV-1) entry
(Montgomery et al., 1996). This assay relies on the use of
Chinese hamster ovary (CHO) cells, which express
GAGs required for virus binding to cells but are resistant
to the entry of certain HSV-1 strains such as HSV-1(KOS)
(Shieh et al., 1992). Expression libraries, or subdivisions
of the libraries, that contain plasmids capable of confer-
ring susceptibility to HSV-1(KOS) can be identified by
transfecting the CHO cells and then assaying for infec-
tion with a recombinant HSV-1(KOS) expressing a re-
porter gene.
The first cell surface protein shown by this assay to
have herpesvirus entry activity is a previously unde-
scribed member of the human TNF receptor family,
which was originally named herpesvirus entry mediator
(HVEM) and is here designated herpesvirus entry protein
A (HveA) for reasons to be discussed below. HveA is a
type I membrane glycoprotein with cysteine-rich repeats
in the ectodomain that are characteristic of the TNF
receptor family (Montgomery et al., 1996) and with a
cytoplasmic domain that can interact with members of
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the TRAF family of signalling molecules (Hsu et al., 1997;
Marsters et al., 1997). HveA is a receptor for two mem-
bers of the TNF family, lymphotoxin a and LIGHT (Mauri
et al., 1998). HveA also binds to isolated HSV-1 or HSV-2
gD and to gD in virions (Nicola et al., 1998; Whitbeck et
al., 1997).
HveA is expressed in many fetal and adult human
tissues, including lung, liver, and kidney (Montgomery et
al., 1996), but appears to be most abundantly expressed
in lymphoid organs and cells (Hsu et al., 1997; Kwon et
al., 1997; Marsters et al., 1997). By use of anti-HveA
antibodies that blocked HSV entry, it was shown that
HveA serves as the principal co-receptor for entry of
HSV-1(KOS) into activated human T lymphocytes (Mont-
gomery et al., 1996). The antibodies did not protect a
number of other human cell types from infection, how-
ever, indicating that there must be other co-receptors for
HSV entry.
Another indication for the existence of multiple indepen-
dent co-receptors for HSV entry was the finding that, al-
though HveA expression in CHO cells enhanced the entry
of all wild-type HSV-1 and HSV-2 strains tested, HveA failed
to mediate the entry of three mutant HSV-1 strains (Mont-
gomery et al., 1996). Two of these strains, designated HSV-
1(KOS)Rid1 and HSV-1(KOS)Rid2 and abbreviated here
KOS-Rid1 and KOS-Rid2, are viable mutants selected for
their ability to overcome interference with viral entry im-
posed by the expression of wild-type HSV-1 gD in cells
(Dean et al., 1994). The third strain, HSV-1(ANG), was iso-
lated from a clinical specimen (Munk and Donner, 1963)
under conditions that would be expected to inhibit the
replication of wild-type HSV (under an overlay of agar con-
taining inhibitory sulfated polysaccharides) and perhaps
select for viral variants. This strain proved to be as resistant
to gD-mediated interference as KOS-Rid1 and KOS-Rid2
(Dean et al., 1994). All three strains have amino acid sub-
stitutions, in gD at position 27 (Q27P or Q27R), that are
sufficient to confer the mutant phenotype of resistance to
gD-mediated interference. Consistent with failure of the
mutant strains to use HveA for entry, the mutant forms of gD
failed to bind HveA, whereas wild-type forms of HSV-1 and
HSV-2 gD were able to bind (Whitbeck et al., 1997). Because
the mutant HSV-1 strains can infect a number of human or
other cell types, despite failure to use HveA for entry, other
co-receptors for entry must be expressed in these cells.
The aims of the studies described here were to isolate
a human co-receptor that is functional for entry of KOS-
Rid1 into resistant CHO cells and to explore the types of
cells and herpesvirus strains for which entry via the new
co-receptor can occur. We found that poliovirus receptor-
related protein 2 (Prr2) (Eberle´ et al., 1995) (designated
here as herpesvirus entry protein B or HveB) was capa-
ble of mediating entry into CHO cells of all three mutant
HSV-I strains, wild-type HSV-2 strains, and pseudorabies
virus (PRV) but had only minimal ability to mediate entry
of wild-type HSV-1 strains and bovine herpesvirus 1
(BHV-1). HveB is widely expressed in human tissues and
cells, including neuronal cells and keratinocytes. In ad-
dition, it may be the only co-receptor expressed in cer-
tain human fibroblasts such as HEL299 cells, inasmuch
as anti-HveB antibodies could protect these cells from
infection.
RESULTS
Failure of KOS-Rid1 to infect CHO cells expressing
HveA
To test whether the inability of KOS-Rid1 to infect
HveA-expressing CHO cells (Montgomery et al., 1996)
was due solely to the known mutation in its gD gene
(Dean et al., 1994), we prepared two virus stocks that
were genotypically gD-negative but complemented with
different forms of gD. KOS-gD6 virus, which has its gD
ORF replaced with the lacZ gene under control of the
CMV promoter, was propagated on complementing Vero
cells expressing either wild-type KOS gD or mutant KOS-
Rid1 gD to obtain the two virus stocks. The stocks were
used to inoculate human HEp-2 cells, HveA-expressing
CHO cells (CHO-HVEM-12), or control CHO cells (CHO-
C8) and viral entry monitored by quantitating b-galacto-
sidase expression. The virus complemented with wild-
type KOS gD was able to infect both HEp-2 and CHO-
HVEM-12 cells, but not CHO-C8 cells, whereas the virus
complemented with KOS-Rid1 gD could infect only the
HEp-2 cells (Fig. 1). Similar results were obtained with
strains KOS/tk12 and KOS-Rid1/tk12, which are recombi-
nants of the original strains modified by the insertion of
a lacZ gene into the viral thymidine kinase gene (data not
shown). The results in Fig. 1 demonstrate that the form of
gD expressed is the sole determinant of the difference in
ability of KOS and KOS-Rid1 to enter cells via HveA,
consistent with the finding that KOS gD binds to HveA,
whereas binding of KOS-Rid1 gD to HveA could not be
detected (Whitbeck et al., 1997). Because KOS gD differs
from KOS-Rid1 and KOS-Rid2 gDs only at amino acid 27,
substitutions at this site must account for the mutant
phenotypes. Virus expressing the KOS-Rid1 form of gD
had reduced ability, compared with virus expressing KOS
gD, to infect human T lymphocytes as well as CHO-
HVEM-12 cells (Montgomery et al., 1996), whereas vi-
ruses expressing either form of gD have a nearly equiv-
alent ability to infect HeLa cells (data not shown) as well
as HEp-2 cells (Fig. 1). Thus, the mutant viruses offered
the opportunity to screen a HeLa cell cDNA library for
plasmids expressing herpesvirus entry proteins other
than HveA.
Cloning and identification of a co-receptor for KOS-
Rid1 entry
The HeLa cell cDNA expression library used previ-
ously to clone HveA (Montgomery et al., 1996) was
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screened again by transfecting CHO-K1 cells with plas-
mid mixtures from the library and then challenging the
cells with KOS-Rid1/tk12 to identify susceptible cells by
b-galactosidase expression. The transfected/inoculated
cells were incubated with X-gal and the monolayers
scored for numbers of blue cells. The numbers of cells
susceptible to KOS-Rid1/tk12 infection in monolayers
transfected with the control plasmid were about 8–13 per
35-mm dish, whereas one of the mixtures of plasmid
pools from the cDNA library converted about 95 cells in
the monolayer to susceptibility to KOS-Rid1/tk12 infec-
tion. The pools in this mixture were individually screened
to identify the one with highest entry activity. This pool
was further subdivided into 100 pools and the process of
screening for entry activity repeated until a single plas-
mid with activity was isolated. This plasmid, designated
pMW347, had a cDNA insert of 1901 base pairs excluding
the poly(A) tail.
Sequencing of the plasmid revealed that it encoded a
protein nearly identical to poliovirus receptor-related pro-
tein 2a (Prr2a), previously cloned on the basis of homol-
ogy to members of the poliovirus receptor subfamily of
the immunoglobulin superfamily. Prr2a and Prr2d are two
membrane glycoproteins expressed from the same locus
and transcript by differential splicing after codon 347
(Eberle´ et al., 1995). Figure 2 shows the main features of
the protein encoded by pMW347, here designated HveB.
The sequence determined for the HveB (Prr2a) open
reading frame (479 amino acids) is identical to that pub-
lished for Prr2a (478 amino acids) except for the pres-
ence of three additional bases following codon 351 such
that codons 352 and 353 of Prr2a (CCT CGC encoding
ProArg) become codons 352, 353, and 354 of HveB (GCC
TCG CCC encoding AlaSerPro).
Susceptibility of cells expressing HveB to entry of
various alphaherpesviruses
CHO-K1 cells either transiently or stably transfected
with an HveB-expressing or control plasmid were inoc-
ulated with recombinant viruses carrying lacZ cassettes
so that susceptibility of the cells to infection could be
assessed by b-galactosidase expression. Alternatively,
CHO-IEb8 cells were transfected with an HveB-express-
ing or control plasmid and inoculated with nonrecombi-
nant viruses. CHO-IEb8 cells carry the lacZ gene under
control of the HSV-1 ICP4 promoter, so that expression of
b-galactosidase is turned on by entry of an HSV strain
FIG. 1. Rid1 mutation in gD blocks HSV-1 entry into HveA-expressing
CHO cells. Hep-2 cells (closed triangles), HveA-expressing CHO-
HVEM-12 cells (closed circles), and control CHO-C8 cells (open
squares) in 96-well plates were inoculated with KOS-gD6 comple-
mented with KOS gD (top) or with KOS-Rid1 gD (bottom). After 6 h, the
cells were permeabilized and substrate (ONPG) was added for quan-
titation of b-galactosidase activity as a measure of viral entry. The
values shown are optical density at 410 nm. Each point is the mean of
triplicate determinations for this and the following figures.
FIG. 2. Features of HveB. The 479-amino-acid translation product has an N-terminal signal sequence, three immunoglobulin-like domains in the
extracellular portion (V, C2, C2), two potential sites for the addition of N-linked glycans (lollipops at positions 137 and 324), a hydrophobic domain that
presumably spans the membrane, and a cytoplasmic tail of 94 amino acids. The amino acid sequence deduced from nucleotide sequence of the
plasmid encoding HveB (GenBank Accession No. AF058448) was nearly identical to that published for Prr2-a (Eberle´ et al., 1995) except as noted
in the text.
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that releases the regulatory protein VP16 from its tegu-
ment into the cell. Figure 3 shows results obtained after
inoculation of transfected CHO-IEb8 cells with a variety
of HSV-1 strains. The HveB-expressing cells (hatched
bars) were susceptible to entry of the mutant strains
KOS-Rid1 and KOS-Rid2 and strain ANG but remained
almost as resistant as the control-transfected cells (open
bars) to entry of the other HSV-1 strains tested. Results
similar to those shown in Fig. 3 have also been obtained
using transiently or stably transfected HveB-expressing
CHO cells and b-galactosidase-expressing recombi-
nants of KOS and KOS-Rid1 (data not shown).
To determine whether HveB could mediate infection by
other alphaherpesviruses, HveB-expressing or control
CHO-IEb8 cells were inoculated with HSV-2 strains 333
and WTW1A and HveB-expressing or control CHO-K1
cells were inoculated with b-galactosidase-expressing
recombinants of BHV-1 and PRV. The results shown in
Fig. 4 demonstrate that HveB expression enhanced the
entry of HSV-2 and PRV but had little effect on BHV-1
entry. Similar results were obtained over a range of input
doses of virus, one of which within the linear range of the
dose response for each virus is shown in Fig. 4. Although
control CHO cells are partially susceptible to HSV-2 entry
(Shieh et al., 1992), as is evident from Fig. 4, enhance-
ment of viral entry was readily observed in HveB-ex-
pressing cells for some, but not all, HSV-2 strains tested.
Lack of enhancement correlated with very high levels of
infection of the control CHO cells, suggesting that HveB
could not contribute appreciably when entry activity was
already very high in its absence. Whether HveB can
independently mediate HSV-2 entry or facilitates entry
via natural co-receptors for HSV-2 expressed by CHO
cells remains to be determined. The former alternative
seems more likely, given the results obtained with HSV-1
mutants and PRV.
Previous results (Montgomery et al., 1996) and those
presented here show that both HveA and HveB enhanced
HSV-2 infection of CHO cells. However, HveA mediated
entry of wild-type HSV-1 strains but not the mutants with
amino acid substitutions at amino acid 27 in gD while the
converse is true for HveB. HveA had no demonstrable
activity in promoting entry of PRV or BHV-1 (Geraghty et al.,
1998), whereas HveB can mediate PRV entry. In a related
study we have shown that poliovirus receptor-related pro-
tein 1 (Prr1), designated HveC, mediated entry of all the
alphaherpesviruses mentioned above and poliovirus recep-
tor (Pvr), also designated Pvr-HveD, mediated entry of PRV
and BHV-1 (Geraghty et al., 1998).
Expression of HveB in various cell types
To detect HveB mRNA in total RNA extracted from
various cultured cell types, reverse transcription fol-
lowed by PCR was performed, using primers that
FIG. 4. Susceptibility of HveB-expressing CHO cells to HSV-2, BHV-1,
and PRV. Cells in 96-well plates were inoculated with serial dilutions of
HSV-2(333), HSV-2(WTW1A), or b-galactosidase-expressing recombi-
nants of BHV-1 or PRV. (A) The cells were CHO-IEb8/HveB (hatched
bar) and CHO-IEb8 (open bar); (B) the cells were CHO-K1 transiently
transfected with HveB-expressing pMW20 (hatched bars) or empty
vector pcDNA3 (open bars). After 6 h, the cells were permeabilized and
incubated with ONPG substrate for quantitation of b-galactosidase
activity as described in Fig. 1 and the text. The results depicted show
entry of virus at a single input dose in the linear range of the dose–
response curve for each virus (3 3 104 PFU/well for both HSV-2 strains,
107 PFU/well for BHV-1 and PRV). Similar results were obtained in at
least two additional experiments for each virus.
FIG. 3. Susceptibility of HveB-expressing CHO cells to entry of
various HSV-1 strains. CHO-IEb8 cells were transfected with HveB-
expressing pMW347 (hatched bars) or empty vector pcDNA3 (open
bars), plated in 96-well plates and then inoculated with serial dilutions
of the viruses indicated. After 6 h, the cells were permeabilized and
incubated with ONPG substrate for quantitation of b-galactosidase
activity as described in Fig. 1 and the text. The results depicted show
entry of virus at a single input dose of 7.5 3 104 PFU per well in the
linear range of the dose–response curve for each virus. The error bars
indicate standard deviation of triplicate determinations.
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spanned three exons of the hveB gene and would gen-
erate a product specific for spliced transcripts from the
hveB locus. A product of the predicted size for the am-
plified HveB mRNA sequence was detected in HveB-
expressing CHO cells, but not in HveA- or HveC-express-
ing CHO cells, as expected (Fig. 5C). This product, indic-
ative of HveB expression, was detected in several human
cell lines, including NT2 (teratocarcinoma), SH-SY5Y
(neuroblastoma), human diploid fibroblasts, HEL299,
HL60, human foreskin keratinocytes, and phytohemag-
glutinin-stimulated human T lymphoblasts (Fig. 5A).
HveC mRNA was detected in all of these cells except for
the T lymphoblasts and HEL299 cells (Geraghty et al.,
1998). It is of interest that one neuroblastoma cell line
(SH-SY5Y) expressed both HveB and HveC mRNAs
whereas another (IMR-5) expressed only HveC mRNA.
Neither HveC nor HveA mRNA (data not shown) could be
detected in HEL299 cells, whereas HveB mRNA was
detected, suggesting that these cells might be resistant
to KOS entry and susceptible to KOS-Rid1 entry via HveB.
Infection of HEL299 cells by KOS-Rid1 and blocking
of infection by anti-HveB antibodies
An HveB-expressing CHO cell line (CHO-HveB-1) and
HEL299 cells were inoculated with serial dilutions of
KOS-gD6 complemented with KOS gD or KOS-Rid1 gD
and viral entry assessed by quantitation of b-galactosi-
dase activity. As expected, the HveB-expressing CHO
cells were susceptible to KOS-gD6 complemented with
KOS-Rid1 gD but not with KOS gD. Similar results were
obtained with the HEL299 cells (Fig. 6), whereas other
cells including HEp-2 (Fig. 1), HT1080, and HveC-ex-
pressing CHO cells (data not shown) were susceptible to
KOS-gD6 complemented with either form of gD.
A rabbit antiserum was raised against a truncated
form of HveB secreted from baculovirus vector-infected
insect cells. Antibodies from the immune serum, but not
pre-immune serum, specifically bound to HveB-express-
ing CHO cells and not to control CHO cells or HveC-
expressing CHO cells (Fig. 7). Because HveB and HveC
are related in structure, it was important to determine
whether the anti-HveB antibodies cross-reacted with
HveC. No evidence for cross-reaction was observed.
Serial dilutions of the antiserum and control serum were
FIG. 6. Susceptibility of HveB-expressing CHO cells and HEL299
cells to KOS-gD6 complemented with KOS-Rid1 gD (circles) but not with
KOS gD (triangles). The cells in 96-well plates were inoculated with
virus at the input doses indicated and, 6 h later, the cells were perme-
abilized and ONPG substrate added for quantitation of b-galactosidase
activity.
FIG. 5. Expression of HveB mRNA in various cell types. Total RNA
was isolated from the cells indicated, cDNAs were produced, and PCR
was performed using primers specific for HveB mRNA (A and C) or
b-actin mRNA (B). The products were separated by electrophoresis on
an agarose gel and then stained with ethidium bromide. Human cells
passaged only a limited number of times in culture included diploid
fibroblasts (HDF), embryonic lung fibroblasts (HEL299), foreskin kera-
tinocytes (HuFK), and T lymphoblasts (HuTL). Human cell lines in-
cluded teratocarcinoma (NT2), neuroblastoma (SH-SY5Y and IMR-5),
and promyelocytic leukemia (HL60). Also shown are results obtained
with RNA extracted from control CHO-K1 cells and stable transfectants
expressing HveA, HveB, or HveC (C). The b-actin controls in B were
also presented in a figure published elsewhere (Geraghty et al., 1998)
that documents expression of HveC mRNA in these cell types.
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incubated with CHO-HveB-1 cells and HEL299 cells fol-
lowed by the addition of KOS-Rid1/tk12 virus. Viral entry
into both cell types was almost completely inhibited by
the antiserum in dose-dependent fashion, whereas the
preimmune serum had no effect or, in the case of
HEL299 cells, actually enhanced entry or events leading
to b-galactosidase expression (Fig. 8). Enhancement of
HSV-1 infection by unknown factors in normal rabbit
serum was also noted for human T lymphoblasts (Mont-
gomery et al., 1996) and is currently unexplained. In the
face of this enhancing activity in rabbit serum, the inhi-
bition of infection of HEL299 cells by the antiserum is
probably even more pronounced than is evident from the
simple dose–response curve (Fig. 8).
DISCUSSION
Use of KOS-Rid1 to screen for a mediator of viral entry
led to identification of Prr2 (Eberle´ et al., 1995) or HveB,
which has entry activity for mutants of HSV-1 altered in
gD, and for HSV-2 and PRV. Because HveB is closely
related to Pvr (Mendelsohn et al., 1989) and Prr1 (Lopez
et al., 1995), we also assessed herpesvirus entry activity
of the latter two proteins in another study (Geraghty et al.,
1998). We found that Prr1 (HveC) could mediate entry of
HSV-1 strains (wild-type and mutants altered in gD),
FIG. 8. Anti-HveB antibodies blocked entry of virus into CHO-HveB-1
cells and HEL299 cells. The cells in 96-well plates were incubated for
30 min with serial dilutions of antiserum R146 (triangles) or preimmune
serum (circles) and then a constant amount of KOS-Rid1/tk12 virus was
added (5 3 105 PFU/well for CHO-HveB-1 cells and 5 3 106 PFU/well
for HEL299 cells). After 2 h of incubation, the virus–serum mixtures
were removed, unpenetrated virus was inactivated by brief treatment
with low pH buffer, and incubation continued for another 4 h. The cells
were permeabilized and ONPG substrate added for quantitation of
b-galactosidase activity.
FIG. 7. Anti-HveB antibodies recognize cell surface HveB but not
HveC. CHO-HveB-4, CHO-HveC-1, and control CHO-K1 cells were de-
tached and incubated with anti-HveB serum R146 (shaded curves) or
with control preimmune serum (open curves), followed by fluorescein-
ated anti-rabbit antibodies. Fluorescence intensity as determined by
flow cytometry is shown. Similar results were obtained with four other
stably transfected CHO-HveB cell lines including CHO-HveB-1 (data not
shown).
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HSV-2 strains, PRV, and BHV-1 and that Pvr (Pvr-HveD)
could mediate entry of PRV and BHV-1. Thus, the three
known human members of the immunoglobulin super-
family that include or are closely related to the Pvr are
able to mediate entry of one or more of the human
and animal alphaherpesviruses used in these studies
(Table 1). Genes for two of these proteins (Pvr-HveD and
HveB) are located on chromosome 19 (Eberle´ et al., 1995;
Koike et al., 1990), whereas HveC is located on chromo-
some 11 (Lopez et al., 1995). The gene for HveC may
have been responsible for the observed ability of chro-
mosome 11 to confer susceptibility to HSV infection on
Chinese hamster lung–human hybrid cells (Francke and
Francke, 1981).
It is somewhat surprising that a member of the TNF
receptor family (HveA) as well as members of the immu-
noglobulin superfamily (HveB and HveC) can mediate
entry of HSV strains, especially because it appears that
gD may be the viral ligand for all these receptors. Evi-
dence has been reported of direct physical interaction
between the ectodomains of HveA and either HSV-1 or
HSV-2 gD (Whitbeck et al., 1997) and of binding of soluble
HveA to virions via interaction with gD (Nicola et al.,
1998). Similar evidence for interaction between the
ectodomains of HveC and gD has also been obtained (C.
Krummenacher, A. V. Nicola, J. C. Whitbeck, H. Lou, W.
Hou, J. D. Lambris, R. J. Geraghty, P. G. Spear, G. H.
Cohen, and R. J. Eisenerg, 1998, Submitted for publica-
tion). Moreover, the allele of gD expressed determines
whether HSV-1 can enter cells via HveA or HveB. Viruses
carrying the wild-type form of gD can infect HveA-ex-
pressing cells, but not HveB-expressing cells, whereas
the converse is true for viruses carrying the Rid mutant
forms (Table 1). In the case of HveA, the fact that HveA
can bind to wild-type gD but not to Rid forms of gD
provides the basis for the observed specificity (Whitbeck
et al., 1997). It remains to be determined whether the
specificity exhibited by HveB is also determined by direct
interactions with HSV-2 gD and the mutant forms of
HSV-1 gD, but not wild-type HSV-1 gD.
Although the PRV and BHV-1 ligands for HveB and
HveC have not been identified, it seems likely that they
will be members of the gD family expressed by these
viruses. The forms of gD expressed by PRV and BHV-1
exhibit only 10 to 15% sequence identity with HSV-1 or
HSV-2 gD. Nevertheless, a gD domain capable of inter-
acting with HveB may be conserved among the HSV-1
Rid mutants, HSV-2 strains, and PRV and another distinct
gD domain capable of interacting with HveC may be
conserved among HSV-1, HSV-2, PRV, and BHV-1. Our
results identify human cell surface proteins by which
these human and animal viruses could penetrate spe-
cific human cells but do not speak to other postentry
requirements for productive or latent infection.
The fact that PRV can use HveB, HveC, and Pvr-HveD,
and BHV-1 can use HveC and Pvr-HveD, for entry into
CHO cells strongly suggests that porcine and bovine
homologs of these human cell surface proteins may be
functional entry proteins for these animal viruses in cells
of the natural host. Homologs of this human subfamily of
the immunoglobulin superfamily have been identified in
monkeys, mice, and rats (Chadeneau et al., 1994; Koike
et al., 1992; Morrison and Racaniello, 1992). Work in
progress (D. Shukla and P. G. Spear, manuscript in prep-
aration) demonstrates that the mouse homolog of HveB,
also known as the murine poliovirus receptor homolog
(Mph) (Morrison and Racaniello, 1992), can mediate the
entry of PRV, suggesting that alphaherpesviruses have
evolved to interact with highly conserved domains and/or
multiple domains of proteins in this receptor subfamily.
Our proposal for the nomenclature of alphaherpesvi-
rus entry proteins is based on several considerations.
First, the names Prr1 and Prr2 are misleading because
these proteins are related to Pvr by sequence but not by
functional activity in poliovirus entry. All three proteins
can serve as alphaherpesvirus entry proteins. Second,
research on the human and animal forms of the multiple
alphaherpesvirus entry proteins will be facilitated by the
assignment of a unique name to each gene encoding
one of these entry proteins (hveA, hveB, hveC, Pvr-HveD),
with use of protein names (HveA, HveB, HveC, Pvr-HveD)
that can be modified as needed to identify the species of
origin (human HveB and mouse HveB, for example).
Clearly, the cross interactions of alphaherpesviruses
with entry proteins of the natural and other hosts will be
easier to track under this system of nomenclature. Fi-
nally, this nomenclature follows the conventions for nam-
ing genes and proteins of multiple loci that encode pro-
teins with apparently equivalent functions (for alphaher-
TABLE 1
Alphaherpesvirus Entry Proteins and Activity for Mediating
Entry of Animal and Human Viruses
Virus
Alphaherpesvirus entry protein (protein family)
HveA (TNF-R)a HveB (Ig) HveC (Ig)b
Pvr-HveD
(Ig)b
HSV-1 1 1 2 2 1 1 1 2 2
HSV-1-Ridc 2 2 1 1 1 1 1 2 2
HSV-2d 1 1 1 1 1 1 ??d
PRV 2 2 1 1 1 1 1 1
BHV-1 2 2 2 2 1 1 1 1
a From results published by Montgomery et al. (1996) and Geraghty
et al. (1998).
b From results published by Geraghty et al. (1998).
c Mutants of HSV-1 with amino acid substitutions at position 27 in gD
(Q27P or Q27R).
d Comparisons of HSV-2 entry activity with activity for entry of the
other viruses is complicated by the partial or full susceptibility of
control CHO cells to HSV-2 entry. Rigorous assessments of compara-
tive activity will have to await use of other cell lines that are as resistant
to HSV-2 as to the other viruses.
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pesvirus entry, at least). Obviously, other functions for
these entry proteins will be defined in the future, at which
time changes in, or additions to, the names may be
appropriate.
Human HveB, HveC, and Pvr-HveD and the animal
homologs studied to date are expressed in many cells
and organs of the intact organism and in a variety of
cultured cell types. Two membrane-bound forms of
HveB, differing in their membrane-spanning regions and
cytoplasmic tails, have been identified (Eberle´ et al.,
1995). Also, multiple membrane-bound and secreted
forms of Pvr-HveD have been identified (Koike et al.,
1990; Mendelsohn et al., 1989). Little is known about the
normal physiological roles of any of these proteins. The
mouse homolog of HveB has been reported to bind to
itself and to mediate homophilic cell aggregation, sug-
gesting that it is a homophilic intercellular adhesion
molecule (Aoki et al., 1997). Interestingly, five indepen-
dently derived stable CHO transfectants cloned for ex-
pression of HveB evolved into populations expressing
both low and high levels of cell surface HveB (see Fig. 7).
If human HveB has the same activity as mouse HveB,
perhaps high-level expression of HveB by all cells in the
population cannot be maintained because of deleterious
effects of intercellular adhesion.
Results presented here and in a related study (Ge-
raghty et al., 1998) indicate that HveB and HveC can be
expressed individually or together in various human cell
types of neuronal, fibroblastic, and epithelial origin. In
these cell types, either or both of these proteins could be
important entry mediators for HSV-2 strains and rare
variant HSV-1 strains, whereas wild-type HSV-1 strains
would be able to use HveC but not HveB. In fact, KOS-
Rid1 but not KOS could infect a human fibroblastic cell
strain, HEL299, via HveB in that antibodies specific for
HveB protected these cells from infection. It seems likely
that the variable ability of different HSV-1 and HSV-2
strains to utilize HveA, HveB, and HveC (and other un-
identified proteins) for entry and variable expression of
these entry proteins in different cell types will govern in
large part any strain-specific and serotype-specific pat-
terns of viral spread in infected persons. Any polymor-
phisms in the genes encoding these proteins might also
contribute to human differences in susceptibility to infec-
tion and disease.
MATERIALS AND METHODS
Cells and viruses
Cell lines used included CHO-K1, HEp-2, Vero, HT1080,
NT2 (Andrews et al., 1984), SH-SY5Y (Ross et al., 1983),
IMR-5 (Gilbert and Malenbaum, 1980), and HL60. Human
cells passaged only a limited number of times from
primary isolation included diploid lung fibroblasts
HEL299 obtained from the American Type Culture Col-
lection (Peterson et al., 1968), diploid fibroblasts obtained
from M. K. Rundell, foreskin keratinocytes obtained from
L. Laimins (Thomas and Laimins, 1998), and T lympho-
blasts (Montgomery et al., 1996). Stable transfectants of
CHO-K1 cells expressed HveA (CHO-HVEM-12) (Mont-
gomery et al., 1996), HveB (CHO-HveB-1 and CHO-HveB-
4), or HveC (CHO-HveC-1) (Geraghty et al., 1998) or
maintained the empty vector pcDNA3 (CHO-C8) (Mont-
gomery et al., 1996). CHO-HveB-1 and -4 cell clones were
transfected with pMW20 as described below. Another
stable CHO-K1 transfectant (CHO-IEb8) maintained a
plasmid with the lacZ gene under control of the HSV-1
ICP4 promoter; expression of b-galactosidase was not
constitutive but was induced by entry of the tegument
transactivator VP16 upon infection by HSV (Montgomery
et al., 1996). Using methods described previously (Terry-
Allison et al., 1998), CHO-IEb8 cells were stably trans-
fected with HveB-expressing pMW20 to yield CHO-IEb8/
HveB cells, which were susceptible to infection by some
HSV strains through constitutive expression of HveB and
remained inducible for expression of b-galactosidase
upon HSV infection. Stable transfectants of Vero cells,
designated Vero15-D1 and Vero14-Rid1, were inducible
for KOS gD or KOS-Rid1 gD expression, respectively, by
infection with HSV. The plasmids used to produce these
complementing cell lines carried the HSV-1 genes for gJ,
gD (wild-type or mutant versions), and gI and the puro-
mycin-resistance marker. For wild-type gD, the insert of
pHD15 (Dean et al., 1994) was excised with SapI and
NdeI and cloned between the same sites in pPUR (In-
vitrogen). For Rid1 gD, the construction was similar ex-
cept the insert used was from pHD31 (Dean et al., 1994).
Wild-type HSV-1 strains used included KOS, F, 17,
SC16, HFEM and Patton. Wild-type HSV-2 strains were
333 and WTW1A. HSV-1(F) (Ejercito et al., 1968) and
HSV-2(WTW1A) (Terhune et al., 1998) have been pas-
saged only a limited number of times in HEp-2 cells
since isolation. HSV-1 strains MP and mP are syncytial
and nonsyncytial strains, respectively, selected as
plaque variants under an antibody overlay (Hoggan and
Roizman, 1959). HSV-1 mutant strains included KOS-Rid1
and KOS-Rid2, both selected for ability to infect gD-
expressing HEp-2 cells and thus for resistance to gD-
mediated interference (Dean et al., 1994). Recombinants
of KOS, KOS-Rid1, and KOS-Rid2 were engineered to
express b-galactosidase under control of the HSV-1 ICP4
promoter; they had the appropriate SalI to BamHI frag-
ment of pON105 (Ho and Mocarski, 1988) inserted be-
tween the SacI and SphI sites (changed to BamHI and
SalI sites) of the viral thymidine kinase gene, replacing
base pairs 47,359 to 47,412 of the viral genome, and
designated KOS/tk12, KOS-Rid1/tk12, and KOS-Rid2/tk12,
respectively. A gD-negative KOS recombinant, desig-
nated KOS-gD6, was engineered to contain the lacZ
gene under control of the CMV promoter inserted be-
tween the HindIII site just upstream of the gD ORF and
the gD stop codon, replacing base pairs 138,349 to
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139,600 of the viral genome. KOS-gD6 was propagated
on Vero15-D1 cells for complementation with KOS gD
and on Vero14-Rid1 cells for complementation with KOS-
Rid1 gD. HSV-1(ANG) was isolated from a lesion on the
thigh by plating under an agar overlay (Munk and Don-
ner, 1963). Animal herpesviruses used were gH-negative
PRV(Kaplan), provided by T. Mettenleiter, and BHV-
1(Cooper)v4a, provided by L. Bello. The PRV recombinant
expressed b-galactosidase under control of the PRV gG
promoter from an insert within the gH gene and was
propagated and titered on complementing gH-express-
ing VeroSW78 cells (Babic et al., 1996). BHV-
1(Cooper)v4a, which expressed b-galactosidase under
control of the BHV-1 gB promoter from an insert within
the viral thymidine kinase gene, was propagated and
titered on MDBK cells (Miller et al., 1995). Except as
noted otherwise, virus strains were propagated on
HEp-2 cells and titered on Vero cells.
Screening assay for plasmids encoding HSV entry
proteins
Bacteria containing a HeLa cell cDNA expression li-
brary (Invitrogen Corp., Catalog No. A950-10) had previ-
ously been divided into 100 pools and frozen as glycerol
stocks as described (Montgomery et al., 1996). Samples
of each pool were combined into groups of 10 and grown
in LB medium with ampicillin and tetracycline and plas-
mids were prepared by standard methods. The plasmid
preparations and pcDNA3 as a control empty vector
were transfected into CHO-K1 cells using LipofectAMINE
reagent (Gibco-BRL) according to the manufacturer’s in-
structions. At 24–36 h after transfection, the cells were
inoculated with KOS-Rid1/tk12 virus at 5 PFU per cell
and, 6 h later, were fixed and stained with X-gal as
described (Montgomery et al., 1996). The number of blue
cells per 35-mm well was counted for each transfection
and averaged for duplicates. Individual stocks in the
plasmid group with greatest activity were tested to iden-
tify the stock with highest activity. This stock was subdi-
vided by plating samples on 100 100-mm plates at about
1000 colonies per plate. The colonies on each plate were
pooled and the process described above repeated until
a single plasmid, designated pMW347, was obtained.
The insert of pMW347 was excised with HindIII and XbaI
and transferred to pcDNA3 to obtain pMW20, which
carried both the insert and a Neo selectable marker.
Nucleotide sequence of the insert was determined by
the University of Chicago Cancer Research Center Se-
quencing Facility, using a UBI Prism 377 DNA sequencer.
The GenBank accession number is AF058448.
Entry assays
Cells were plated in 96-well plates and, after overnight
incubation, were inoculated with virus serially diluted in
phosphate-buffered saline containing 0.1% glucose and
1% calf serum (PBS-G-CS) and incubated at 37°C. When
antibodies were tested for the ability to protect cells from
infection, serial dilutions of antiserum prepared in PBS-
G-CS were incubated with the cells for 30 min at 37°C
followed by the addition of virus. After 2 h of incubation
with the virus–antiserum mixtures, the mixtures were
removed and the cells treated with 0.1 M citrate buffer
(pH 3) to inactivate unpenetrated virus and then washed.
PBS-G-CS was added for continued incubation. Recom-
binant viruses expressing b-galactosidase were used for
all cell types except CHO-IEb8. Because CHO-IEb8 cells
express b-galactosidase from a cell-associated reporter
gene upon entry of HSV, viruses without reporter genes
could be used on these cells. Six hours after the addition
of virus, the cells were washed and incubated with the
b-galactosidase substrate O-nitrophenyl b-d-galactopy-
ranoside (ONPG), dissolved at 3 mg/ml in phosphate-
buffered saline containing 0.5% NP-40. At various times
after adding substrate, the plates were read at 410 nm in
a Spectra Max 250 ELISA reader.
Detection of mRNAs by RT-PCR
Total RNA was isolated from 1 3 106 to 5 3 106 cells
using the RNeasy kit (Qiagen). The 39 RACE kit (Gibco-
BRL) was used for reverse transcription. PCR amplifica-
tion of cDNAs was done with primers PRR2A8
(59AGAAGCAGCAGCACCAGCAG) and PRR2A9 (59AAG-
GTCACGTTCAGCCAGGA) for HveB and HVEM228 (59AT-
CATATGTGTGAAAAGAAGA) and HHVENT03 (59CAGGT-
TATCGTGTGAAGGAG) for HveA. The b-actin control
primers and thermocycling conditions have been de-
scribed (Willey et al., 1996). The PCR products were
analyzed by electrophoresis on a 1% agarose gel and
visualized by ethidium bromide staining.
Construction of the baculovirus recombinant
expressing HveB(361t)
The general strategy was as described for construc-
tion of a baculovirus recombinant expressing a secreted
form of HSV-1 gD (Sisk et al., 1994). The ectodomain of
HveB minus its signal peptide was obtained by PCR
amplification using primers 59-GCGAGATCTGCGAGT-
TCAAGTGCTA and 59-GCGTGATCAGTGGTGATGATGGT-
GATGCACCAGCGGACCCACATCTC. The PCR product
was digested with BglII and BclI (sites indicated by
boldface letters) and inserted into the BamHI site of
pVT-Bac to generate pCW284. pVT-Bac fuses a mellitin
signal sequence to the N-terminus of an inserted coding
region and a histidine hexamer to the C-terminus. The
plasmid pCW284 was cotransfected with baculovirus
DNA (Baculogold, Pharmingen) into Sf9 cells growing in
monoloyer culture. Viral progeny were screened for ex-
pression of the secreted recombinant protein HveB(361t)
by Western blot with R143 antiserum and positive clones
were plaque-purified. Bac-HveB(361t) was the viral re-
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combinant used routinely for preparation of purified
HveB(361t). This recombinant protein comprising amino
acids 33 to 361 of the HveB ectodomain was purified
from the medium of infected Sf9 cells by chromatography
on nickel-NTA resin (Qiagen), dialyzed against PBS, and
concentrated as described previously (Sisk et al., 1994).
Antibodies and flow cytometry
Antiserum R143 was generated by immunizing a rabbit
with KLH coupled to a 22-amino-acid peptide (DVRVQV-
LPEVRGQLGGTVELPC) representing a hydrophilic por-
tion of the HveB ectodomain. This antiserum recognized
the peptide used for immunization by dot blot assay and
HveB(361t) by Western blot. Antiserum R146 was gener-
ated by immunization of a rabbit with purified HveB(361t)
as previously described for HVEM(200t) (Terry-Allison et
al., 1998). Specific binding of antibodies (antiserum R146)
to HveB on cell surfaces was assessed by flow cytom-
etry. The antiserum and preimmune serum were diluted
1:100 and incubated with the cells. After washing the
cells were incubated with a 1:200 dilution of fluorescein-
ated goat anti-rabbit antibodies and analyzed on a Bec-
ton–Dickinson FACScan.
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